Unknown

Dataset Information

0

Application of gene-editing technologies to HIV-1.


ABSTRACT: This review will highlight some of the recent advances in genome engineering with applications for both clinical and basic science investigations of HIV-1.Over the last year, the field of HIV cure research has seen major breakthroughs with the success of the first phase I clinical trial involving gene editing of CCR5 in patient-derived CD4(+) T cells. This first human use of gene-editing technology was accomplished using zinc finger nucleases (ZFNs). Zinc finger nucleases and the advent of additional tools for genome engineering, including transcription activator-like effector nucleases (TALENS) and the clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 system, have made gene editing remarkably simple and affordable. Here we will discuss the different gene-editing technologies, the use of gene editing in HIV research over the past year, and potential applications of gene editing for both in-vitro and in-vivo studies.Genome-engineering technologies have rapidly progressed over the past few years such that these systems can be easily applied in any laboratory for a variety of purposes. For HIV-1, upcoming clinical trials will determine if gene editing can provide the long-awaited functional cure. In addition, manipulation of host genomes, whether in vivo or in vitro, can facilitate development of better animal models and culture methods for studying HIV-1 transmission, pathogenesis, and virus-host interactions.

SUBMITTER: Drake MJ 

PROVIDER: S-EPMC4420178 | biostudies-other | 2015 Mar

REPOSITORIES: biostudies-other

altmetric image

Publications

Application of gene-editing technologies to HIV-1.

Drake Mary Jane MJ   Bates Paul P  

Current opinion in HIV and AIDS 20150301 2


<h4>Purpose of review</h4>This review will highlight some of the recent advances in genome engineering with applications for both clinical and basic science investigations of HIV-1.<h4>Recent findings</h4>Over the last year, the field of HIV cure research has seen major breakthroughs with the success of the first phase I clinical trial involving gene editing of CCR5 in patient-derived CD4(+) T cells. This first human use of gene-editing technology was accomplished using zinc finger nucleases (ZF  ...[more]

Similar Datasets

| S-EPMC3856413 | biostudies-literature
| S-EPMC8684261 | biostudies-literature
| S-EPMC4595993 | biostudies-other
| S-EPMC4786923 | biostudies-other
| S-EPMC4999461 | biostudies-literature
| S-EPMC6439341 | biostudies-literature
| S-EPMC7062760 | biostudies-literature
| S-EPMC9747045 | biostudies-literature
| S-EPMC8099660 | biostudies-literature
| S-EPMC5131771 | biostudies-literature